Zaid S Al-Kadhimi, MD

Associate Professor

  • 651 Citations
  • 16 h-Index
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Zaid S Al-Kadhimi is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 26 Similar Profiles
Graft vs Host Disease Medicine & Life Sciences
Transplants Medicine & Life Sciences
Tacrolimus Medicine & Life Sciences
Stem Cell Transplantation Medicine & Life Sciences
T-Lymphocytes Medicine & Life Sciences
Mycophenolic Acid Medicine & Life Sciences
Hematopoietic Stem Cell Transplantation Medicine & Life Sciences
Melphalan Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2004 2020

  • 651 Citations
  • 16 h-Index
  • 31 Article
  • 8 Review article
  • 3 Letter

Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Holstein, S. A., Al-Kadhimi, Z., Costa, L. J., Hahn, T., Hari, P., Hillengass, J., Jacob, A., Munshi, N. C., Oliva, S., Pasquini, M. C., Shi, Q., Stadtmauer, E. A., Waldvogel, S. L. & McCarthy, P. L., Jan 2020, In : Biology of Blood and Marrow Transplantation. 26, 1, p. e7-e15

Research output: Contribution to journalReview article

Residual Neoplasm
Bone Marrow
Clinical Trials

Intensity of chemotherapy for the initial management of newly diagnosed acute myeloid leukemia in older patients

Michalski, J. M., Lyden, E. R., Lee, A. J., Al-Kadhimi, Z. S., Maness, L. J., Gundabolu, K. & Bhatt, V. R., Jun 2019, In : Future Oncology. 15, 17, p. 1989-1995 7 p.

Research output: Contribution to journalArticle

Acute Myeloid Leukemia
Drug Therapy
16 Citations (Scopus)

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

Bolaños-Meade, J., Reshef, R., Fraser, R., Fei, M., Abhyankar, S., Al-Kadhimi, Z., Alousi, A. M., Antin, J. H., Arai, S., Bickett, K., Chen, Y. B., Damon, L. E., Efebera, Y. A., Geller, N. L., Giralt, S. A., Hari, P., Holtan, S. G., Horowitz, M. M., Jacobsohn, D. A., Jones, R. J. & 14 others, Liesveld, J. L., Logan, B. R., MacMillan, M. L., Mielcarek, M., Noel, P., Pidala, J., Porter, D. L., Pusic, I., Sobecks, R., Solomon, S. R., Weisdorf, D. J., Wu, J., Pasquini, M. C. & Koreth, J., Mar 2019, In : The Lancet Haematology. 6, 3, p. e132-e143

Research output: Contribution to journalArticle

Mycophenolic Acid
Cell Transplantation
Graft vs Host Disease

A phase II study of tacrolimus and thymoglobulin as graft-versus-host-disease prophylaxis in related donor allogeneic hematopoietic cell transplantation

Modi, D., Al-Kadhimi, Z., Chen, W., Jang, H., Deol, A., Ayash, L., Bhutani, D., Alavi, A., Ratanatharathorn, V. & Uberti, J. P., Apr 2018, In : American Journal of Hematology. 93, 4, p. E96-E98

Research output: Contribution to journalLetter

Cell Transplantation
Graft vs Host Disease
4 Citations (Scopus)

Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Hosoba, S., Waller, E. K., Shenvi, N., Graiser, M., Easley, K. A., Al-Kadhimi, Z., Andoh, A., Antun, A. G., Barclay, S., Josephson, C. D., Koff, J. L., Khoury, H. J., Langston, A. A., Zimring, J. C., Roback, J. D. & Giver, C. R., May 2018, In : Biology of Blood and Marrow Transplantation. 24, 5, p. 973-982 10 p.

Research output: Contribution to journalArticle

Erythrocyte Transfusion
Hematopoietic Stem Cell Transplantation
Graft vs Host Disease
Confidence Intervals